Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2015

01-06-2015 | Case Report

Primary Follicular Lymphoma of the Breast: A Rare Clinical Entity Diagnosed Using Tissue Flow Cytometry

Authors: Shivani Sharma, Pranav Dorwal, Ritesh Sachdev, Amit Pande, Neetu Tyagi, Dharmendra Jain, Vimarsh Raina

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2015

Login to get access

Excerpt

Primary breast lymphomas are a rare entity and constitute less than 1 % of all the non-Hodgkin’s lymphomas, <0.5 % of all breast malignancies and <5 % of extranodal lymphomas [1]. The predominant type of primary breast lymphoma is Diffuse Large B cell Lymphoma (DLBCL), while Follicular Lymphoma (FL) is a still rarer entity. In the study conducted by International Extranodal Lymphoma Study Group (IELSG), on Primary Breast Lymphomas, FL constitute 12.9 % of total 278 cases [1]. …
Literature
1.
go back to reference Martinelli G, Ryan G, Seymour JF, Nassi L et al (2009) Primary follicular and marginal zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by International extranodal lymphoma study group. Ann Oncol 20(12):1993–2000CrossRefPubMed Martinelli G, Ryan G, Seymour JF, Nassi L et al (2009) Primary follicular and marginal zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by International extranodal lymphoma study group. Ann Oncol 20(12):1993–2000CrossRefPubMed
2.
go back to reference Ray S, Craig FE, Swerdlow SH (2005) Abnormal patterns of antigen expression in follicular lymphoma. Am J Clin Pathol 124:576–583CrossRefPubMed Ray S, Craig FE, Swerdlow SH (2005) Abnormal patterns of antigen expression in follicular lymphoma. Am J Clin Pathol 124:576–583CrossRefPubMed
3.
go back to reference Topalovski M, Crisan D, Mattson JC (1999) Lymphoma of the breast: a clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123:1208–1218PubMed Topalovski M, Crisan D, Mattson JC (1999) Lymphoma of the breast: a clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123:1208–1218PubMed
4.
go back to reference Swart GJ, Wright C, Brundyn K, Mansvelt E et al (2007) Fine needle aspiration biopsy and flow Cytometry in the diagnosis of lymphoma. Transfus Apheres Sci 37(1):71–79CrossRef Swart GJ, Wright C, Brundyn K, Mansvelt E et al (2007) Fine needle aspiration biopsy and flow Cytometry in the diagnosis of lymphoma. Transfus Apheres Sci 37(1):71–79CrossRef
5.
go back to reference Cornfield DB, Mitchell DM, Almasri NM, Anderson JB et al (2000) Follicular lymphoma can be distinguished from benign follicular hyperplasia by flow Cytometry using simultaneous staining of cytoplasmic bcl-2 and cell surface CD20. Am J Clin Pathol 114:258–263CrossRefPubMed Cornfield DB, Mitchell DM, Almasri NM, Anderson JB et al (2000) Follicular lymphoma can be distinguished from benign follicular hyperplasia by flow Cytometry using simultaneous staining of cytoplasmic bcl-2 and cell surface CD20. Am J Clin Pathol 114:258–263CrossRefPubMed
6.
go back to reference Mourad WA, Rawas F, Shoukri M, Tbakhi A et al (2006) Grading of follicular lymphoma using flow cytometry. Ann Saudi Med 26(3):205–210 Mourad WA, Rawas F, Shoukri M, Tbakhi A et al (2006) Grading of follicular lymphoma using flow cytometry. Ann Saudi Med 26(3):205–210
Metadata
Title
Primary Follicular Lymphoma of the Breast: A Rare Clinical Entity Diagnosed Using Tissue Flow Cytometry
Authors
Shivani Sharma
Pranav Dorwal
Ritesh Sachdev
Amit Pande
Neetu Tyagi
Dharmendra Jain
Vimarsh Raina
Publication date
01-06-2015
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2015
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0463-4

Other articles of this Issue 2/2015

Indian Journal of Hematology and Blood Transfusion 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine